FDA Settles Lawsuit Over Ivermectin Social Media Guidance
Is this a scandal?
No longer — the story is resolved: noise 2/100 · state: Case Closed · 1 source item across 1 platform · peaked at 41/100 on May 28, 2026. — as of , measured by the SCAND.Ai noise pipeline.
Incident ID: SCAND-137110
Cite this incident
"FDA Settles Lawsuit Over Ivermectin Social Media Guidance." SCAND.Ai incident SCAND-137110, noise 2/100 as of June 10, 2026. https://scand.ai/scandal/fda-ivermectin-lawsuit-settlementWhy It Matters
This settlement establishes a legal boundary for federal agencies regarding their influence over medical practice and off-label prescriptions. It highlights the tension between public health messaging and the professional autonomy of licensed physicians.
Key Points
- The FDA agreed to delete social media posts and web content advising against ivermectin for COVID-19.
- The settlement originated from a lawsuit filed by Dr. Mary Talley Bowden and two other physicians.
- Plaintiffs argued the FDA violated federal law by interfering with the practice of medicine and physician autonomy.
- The legal victory centers on the limits of federal agency authority over state-licensed medical professionals.
The U.S. Food and Drug Administration (FDA) has settled a lawsuit brought by three physicians by agreeing to remove specific social media posts and website content that advised against the use of ivermectin for COVID-19 treatment. The settlement, finalized in March 2024, concludes a legal challenge led by Dr. Mary Talley Bowden and others who argued the agency exceeded its regulatory mandate. The plaintiffs contended that the FDA messaging unlawfully interfered with the private doctor-patient relationship and traditional medical practice. While the FDA maintains its position that clinical trials do not support ivermectin as an effective COVID-19 treatment, the legal resolution focuses on the limits of an agency's authority to direct prescribing practices. The agreement requires the permanent removal of several high-profile public warnings from the agency's official digital channels. This case underscores the ongoing debate regarding federal authority in medical oversight.
The FDA had to delete its viral posts about ivermectin after getting sued by doctors who claimed the agency overstepped its bounds. The doctors argued that while the FDA can approve drugs, it isn't allowed to tell doctors how to practice medicine or what they can prescribe to patients. It is like a referee trying to play the game instead of just enforcing the rules. The FDA did not change its scientific stance on the drug, but it admitted it went too far in how it tried to influence prescribing habits through public messaging.
Sides
Critics
Led the lawsuit claiming the FDA overstepped its legal authority and harmed the doctor-patient relationship.
Legal counsel for the doctors who argued the FDA cannot lawfully interfere with physician prescribing practices.
Defenders
Argued it had the authority to provide public health information but settled to remove specific posts to end the litigation.
Noise Level
Forecast
This settlement will likely embolden future legal challenges against federal health guidance that provides prescriptive advice. Expect more litigation regarding the boundary between drug regulation and the practice of medicine during future public health crises.
Based on current signals. Events may develop differently.
Timeline
Settlement Reached
The FDA agrees to remove the controversial social media posts and website content to settle the lawsuit.
Appellate Court Ruling
The 5th U.S. Circuit Court of Appeals rules that the FDA does not have the authority to advise against off-label prescriptions.
Lawsuit Filed
Three doctors file a lawsuit against the FDA alleging the agency interfered with their ability to practice medicine.
FDA Social Media Campaign
The FDA publishes 'You are not a horse' social media posts discouraging the use of ivermectin for COVID-19.
Join the Discussion
Discuss this story
Community comments coming in a future update
Be the first to share your perspective. Subscribe to comment.